Palomino Laboratories Inc.
PALX· OTC
PALXPalomino Laboratories Inc.
Source filing unavailable
| Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Net Income | -$4.25K | -$4.25K |
| EPS Diluted | -$0.00 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palomino Laboratories Inc. · CIK 1938569 · Engraved from SEC EDGAR
